Jonas A Nilsson

List of Publications by Year
in descending order

76 papers	8,073 citations	81743 39 h-index	66788 78 g-index
84 all docs	84 docs citations	84 times ranked	15500 citing authors

#	Article	IF	Citations
1	Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma. Melanoma Research, 2022, 32, 241-248.	0.6	9
2	A Fraction of CD8+ T Cells from Colorectal Liver Metastases Preferentially Repopulate Autologous Patient-Derived Xenograft Tumors as Tissue-Resident Memory T Cells. Cancers, 2022, 14, 2882.	1.7	3
3	BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma. Epigenetics, 2021, 16, 54-63.	1.3	3
4	Discovery of a rare <i>GKAP1-NTRK2</i> fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib. Cancer Biology and Therapy, 2021, 22, 184-195.	1.5	7
5	The Microenvironment of Small Intestinal Neuroendocrine Tumours Contains Lymphocytes Capable of Recognition and Activation after Expansion. Cancers, 2021, 13, 4305.	1.7	7
6	The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nature Communications, 2021, 12, 5155.	5.8	85
7	Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma. American Journal of Pathology, 2021, 191, 2023-2038.	1.9	13
8	Reply to Comment on Katsarelias, D., et al. â€œThe Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanomaâ€"A Nation-Wide Swedish Population-Based Retrospective Register Study.â€• Cancers 2020, 12, 3228. Cancers, 2021, 13, 92.	1.7	1
9	The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanomaâ€"A Nation-Wide Swedish Population-Based Retrospective Register Study. Cancers, 2020, 12, 3228.	1.7	9
10	Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. Annals of Oncology, 2020, 31, 266-273.	0.6	26
11	Molecular profiling of driver events in metastatic uveal melanoma. Nature Communications, 2020, 11, 1894.	5.8	108
12	SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut, 2020, 69, 1472-1482.	6.1	61
13	Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells. Life Science Alliance, 2020, 3, e202000671.	1.3	4
14	H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines. Nature Genetics, 2019, 51, 1426-1427.	9.4	4
15	Endosomal signalling via exosome surface TGFÎ²â€1. Journal of Extracellular Vesicles, 2019, 8, 1650458.	5.5	112
16	Clinical, genetic and experimental studies of the Brookeâ€"Spiegler (CYLD) skin tumor syndrome. Journal of Plastic Surgery and Hand Surgery, 2019, 53, 71-75.	0.4	3
17	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. BMC Cancer, 2019, 19, 415.	1.1	49
18	BRAF status as a predictive factor for response in isolated limb perfusion. International Journal of Hyperthermia, 2019, 36, 510-514.	1.1	2

#	Article	IF	Citations
19	HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapyâ€"Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Cancer Research, 2019, 79, 899-904.	0.4	84
20	Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma. Annals of Surgical Oncology, 2019, 26, 1055-1062.	0.7	10
21	Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary. JCO Precision Oncology, 2018, 2, 1-25.	1.5	10
22	A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. Cell Death and Disease, 2018, 9, 810.	2.7	38
23	Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2. Frontiers in Oncology, 2018, 8, 218.	1.3	25
24	Complement peptide C3a stimulates neural plasticity after experimental brain ischaemia. Brain, 2017, 140, 353-369.	3.7	106
25	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nature Communications, 2017, 8, 707.	5.8	123
26	An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nature Medicine, 2017, 23, 929-937.	15.2	146
27	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. Cell Death and Disease, 2017, 8, e2982-e2982.	2.7	17
28	Pathogenesis and therapeutic targeting of aberrant <scp>MYC</scp> expression in haematological cancers. British Journal of Haematology, 2017, 179, 724-738.	1.2	36
29	BRAF ^{V600} inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5930-E5939.	3.3	101
30	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNÎ³ Signaling. Cancer Research, 2017, 77, 4562-4566.	0.4	39
31	Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. Annals of Surgical Oncology, 2016, 23, 1327-1334.	0.7	24
32	Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13768-13773.	3.3	50
33	RNAi delivery by exosome-mimetic nanovesicles â€" Implications for targeting c-Myc in cancer. Biomaterials, 2016, 102, 231-238.	5.7	188
34	Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. Cancer Research, 2016, 76, 2376-2383.	0.4	15
35	Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. Oncotarget, 2016, 7, 23801-23811.	0.8	13
36	DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor STING to Promote Anti-Microbial Innate Immunity. Immunity, 2015, 42, 332-343.	6.6	567

#	Article	IF	Citations
37	Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells â€“ Evidence of unique microRNA cargos. RNA Biology, 2015, 12, 810-823.	1.5	164
38	Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes. Immunity, 2015, 43, 647-659.	6.6	72
39	Antioxidants can increase melanoma metastasis in mice. Science Translational Medicine, 2015, 7, 308re8.	5.8	468
40	BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2721-30.	3.3	204
41	MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature, 2014, 508, 215-221.	13.7	419
42	Antioxidants Accelerate Lung Cancer Progression in Mice. Science Translational Medicine, 2014, 6, 221ra15.	5.8	663
43	Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nature Genetics, 2014, 46, 1258-1263.	9.4	269
44	Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials, 2014, 15, 317.	0.7	33
45	Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood, 2014, 124, 2081-2090.	0.6	72
46	Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. Oncotarget, 2014, 5, 9609-9618.	0.8	62
47	Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors. ACS Nano, 2013, 7, 7698-7710.	7.3	768
48	Mouse Genetics Suggests Cell-Context Dependency for Myc-Regulated Metabolic Enzymes during Tumorigenesis. PLoS Genetics, 2012, 8, e1002573.	1.5	75
49	Cks1 Is Required for Tumor Cell Proliferation but Not Sufficient to Induce Hematopoietic Malignancies. PLoS ONE, 2012, 7, e37433.	1.1	14
50	Inhibition of cellular FLICE-like inhibitory protein abolishes insensitivity to interferon-Î± and death receptor stimulation in resistant variants of the human U937 cell line. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 783-794.	2.2	2
51	Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells. Clinical Cancer Research, 2011, 17, 7067-7079.	3.2	124
52	Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. Cell Cycle, 2011, 10, 3598-3607.	1.3	31
53	The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget, 2011, 2, 448-460.	0.8	45
54	Skp2 Directs Myc-Mediated Suppression of p27Kip1 yet Has Modest Effects on Myc-Driven Lymphomagenesis. Molecular Cancer Research, 2010, 8, 353-362.	1.5	26

#	Article	IF	Citations
55	Chemoprevention of B-Cell Lymphomas by Inhibition of the Myc Target Spermidine Synthase. Cancer Prevention Research, 2010, 3, 140-147.	0.7	42
56	Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood, 2010, 116, 1498-1505.	0.6	196
57	Reduced <i>FAS</i> transcription in clones of U937 cells that have acquired resistance to Fasâ€induced apoptosis. FEBS Journal, 2009, 276, 497-508.	2.2	5
58	Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood, 2009, 113, 4281-4288.	0.6	31
59	Selection against <i>PUMA</i> Gene Expression in Myc-Driven B-Cell Lymphomagenesis. Molecular and Cellular Biology, 2008, 28, 5391-5402.	1.1	130
60	Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO Journal, 2007, 26, 2562-2574.	3.5	88
61	Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. Journal of Neurochemistry, 2006, 99, 677-688.	2.1	27
62	Nfkb1 is dispensable for Myc-induced lymphomagenesis. Oncogene, 2005, 24, 6231-6240.	2.6	36
63	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 2005, 436, 807-811.	13.7	419
64	Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell, 2005, 7, 433-444.	7.7	179
65	The Novel ETS Factor TEL2 Cooperates with Myc in B Lymphomagenesis. Molecular and Cellular Biology, 2005, 25, 2395-2405.	1.1	61
66	Mnt Loss Triggers Myc Transcription Targets, Proliferation, Apoptosis, and Transformation. Molecular and Cellular Biology, 2004, 24, 1560-1569.	1.1	85
67	Id2 Is Dispensable for Myc-Induced Lymphomagenesis. Cancer Research, 2004, 64, 7296-7301.	0.4	18
68	Mnt: Master Regulator of the Max Network. Cell Cycle, 2004, 3, 586-588.	1.3	11
69	Mnt: master regulator of the Max network. Cell Cycle, 2004, 3, 588-90.	1.3	5
70	Myc pathways provoking cell suicide and cancer. Oncogene, 2003, 22, 9007-9021.	2.6	420
71	c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-XL. Molecular and Cellular Biology, 2003, 23, 7256-7270.	1.1	123
72	c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes and Development, 2002, 16, 2530-2543.	2.7	409

#	Article	IF	Citations
73	Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen. British Journal of Pharmacology, 2001, 133, 513-520.	2.7	36
74	Antizyme inhibitor is rapidly induced in growth-stimulated mouse fibroblasts and releases ornithine decarboxylase from antizyme suppression. Biochemical Journal, 2000, 346, 699-704.	1.7	65
75	Skin fibroblasts from spermine synthase-deficient hemizygous gyro male (Gy/Y) mice overproduce spermidine and exhibit increased resistance to oxidative stress but decreased resistance to UV irradiation. Biochemical Journal, 2000, 352, 381-387.	1.7	24
76	Polyamines Regulate Both Transcription and Translation of the Gene Encoding Ornithine Decarboxylase Antizyme in Mouse. FEBS Journal, 1997, 250, 223-231.	0.2	36